Joshua Davis

@Josh_S_Davis

Infectious Diseases physician, clinical researcher - clinical trials, SAB, PJI, sepsis, viral hep. #IDTwitter @snap_trial @ASCOT_trial @ASIDANZ

Newcastle, Darwin (Australia) menzies.edu.au/page/Our_Peopl… Joined March 2015

378 Following 4.3K Followers 1.6K Posts

Latest posts 5

Joshua Davis @Josh_S_Davis Sep 3

I had fun today going on my child's radio show where guests talk about (and listen to) 5 songs that are formative to them - give it a listen!
mixcloud.com/RadioFodder_/b…

www.mixcloud.com backtrack, s2e5: josh (father's day special!) by Radio Fodder originally broadcast 03/09/2026. sharing songs each week that remind us of time gone by: this week with my dad. today, backtrack goes intergenerational. one of the biggest influences on my own music...

Joshua Davis @Josh_S_Davis May 12

Hi all #IDXposts #IDTwitter peeps. For those of you who missed out on #ESCMIDglobal this year (or who went and want a summary), see the highlights of ESCMID Global 2026 from the CLARITY faculty clarityinitiative.org/english-versio…

clarityinitiative.org Highlights of ESCMID Global 2026 from the CLARITY faculty ESCMID Global 2026 in Munich has shown definitively that it is now the premier infectious diseases meeting in the world (and has been for a while): Over 18,000 delegates, hundreds of high-impact...

Joshua Davis @Josh_S_Davis Apr 23

Was great catching up with friends old and new at #ESCMIDglobal2026. But embarrassing as an Aussie to be outdone in beer drinking by an American! (The famous Tom Holland)

Joshua Davis @Josh_S_Davis Apr 20

@davidantibiotic at #ESCMIDGlobal2026 about MERINO trial: calling out the haters on Twitter(X): Remember that there are honest investigators on the receving end of all your criticisms. Please keep it respectful!

Joshua Davis @Josh_S_Davis Apr 20

ASATARTE trial at #ESCMIDGlobal2026. Previous data presented 2025- Temocillin non-inferior to carbepenems for 3GC-R E.coli or Klebsiella. Now comparing ertapanam with meropenem (clinician choice) post-hoc. No difference in outcomes BUT meropenem group younger but sicker. . . .